轉甲狀腺素類澱粉沉積症治療市場規模、佔有率和成長分析：按藥物類型、疾病類型、應用、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球轉甲狀腺素類澱粉沉積症樣變性治療市場價值為 72 億美元，預計到 2033 年將從 2025 年的 82 億美元成長到 232.3 億美元，預測期（2026-2033 年）的複合年成長率為 13.9%。

轉甲狀腺素類澱粉沉積症治療市場主要由創新的疾病修正治療驅動，這些療法將治療重點從症狀治療轉向延緩疾病進展。目前的治療方法著重於蛋白質穩定、RNA定序和替代療法等技術，鑑於患者面臨嚴重的心臟和神經功能衰退，市場至關重要。診斷技術的進步，包括非侵入性心臟影像和基因檢測，正在促進病例識別，而tafamidis和patisiran等治療方法的核准推動了投資和研發。不斷擴展的診斷體系帶來了更可靠的檢測和臨床效益，從而促進了治療方法的應用。此外，人工智慧透過改進標靶分析和最佳化患者群，加速了藥物發現和患者分層，減少了臨床試驗中的低效環節。這些趨勢為基因治療和合作創造了機遇，擴大了服務不足地區獲得有效治療的機會。

全球轉甲狀腺素類澱粉沉積症治療市場的成長要素

全球轉甲狀腺素類澱粉沉積症（ATTR）治療市場的主要促進因素是此疾病盛行率的不斷上升。由於ATTR的症狀多樣且複雜，因此常被誤診。醫療專業人員和患者對ATTR的認知和理解不斷提高，促使診斷更加準確，也增加了對有效治療方法的需求。此外，藥物研發和生物技術的進步正在推出新的治療方法，顯著改善患者的治療效果，進一步推動了市場成長。對早期檢測和個人化治療方案的日益重視也推動了ATTR治療領域的投資和創新。

全球轉甲狀腺素類澱粉沉積症治療市場的限制因素

全球轉甲狀腺素類澱粉沉積症變性治療市場的主要限制因素之一是治療方法和治療方案的高成本。這些治療方法，特別是創新生物製藥和基因療法，通常價格昂貴，限制了患者和醫療系統的可及性，尤其是在中低收入地區。此外，轉甲狀腺素類澱粉沉積症樣變性的診斷複雜性也會延誤治療的啟動，進而降低醫療機構的投資意願。高昂的成本和診斷難題相結合，可能會阻礙市場成長，因為更多患者可能難以獲得及時有效的治療。

全球轉甲狀腺素類澱粉沉積症樣變性治療市場趨勢

在全球轉甲狀腺素類澱粉沉積症樣變性治療市場中，精準診斷技術的進步正推動著重大變革。分子診斷和生物標記分析的創新使得疾病表現型的早期準確識別成為可能，從而促進了個人化治療方法方案的選擇。這一趨勢正在推動診斷公司、專科醫療中心和製藥研發公司之間的合作，進而改善治療效果。此外，將基因檢測整合到臨床路徑中，正在重塑患者照護，使其更有效率有效。隨著醫療服務提供者和保險公司擴大採用以診斷主導的護理模式，關注點正轉向在確保患者整個治療過程中資源永續分配的同時，最佳化治療效果。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球轉甲狀腺素類澱粉沉積症治療藥物市場規模：依藥物類型分類

• 轉甲狀腺素穩定劑
• 基因靜默療法
• 單株抗體
• 支持性護理
• 其他

全球轉甲狀腺素類澱粉沉積症變性治療市場規模：依疾病類型分類

• 遺傳性ATTR類澱粉沉積症
• 野生型ATTR類澱粉沉積症

全球轉甲狀腺素類澱粉沉積症治療市場規模：按應用領域分類

• 多發性神經病變
• 心肌病
• 混合型

全球轉甲狀腺素類澱粉沉積症治療市場規模：依給藥途徑分類

• 口服
• 靜脈
• 皮下

全球轉甲狀腺素類澱粉沉積症治療市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 專科藥房
• 網路藥房

全球轉甲狀腺素類澱粉沉積症治療市場規模：依最終用戶分類

• 醫院
• 專科診所
• 門診部
• 居家醫療

全球轉甲狀腺素類澱粉沉積症治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Alnylam Pharmaceuticals
• Pfizer
• BridgeBio Pharma
• AstraZeneca
• Ionis Pharmaceuticals
• Intellia Therapeutics
• Novo Nordisk
• Neurimmune
• Prothena Corporation
• Eidos Therapeutics
• Arrowhead Pharmaceuticals
• Corino Therapeutics
• SOM Biotech
• Akcea Therapeutics
• Alexion Pharmaceuticals
• GlaxoSmithKline
• Bayer
• Regeneron Pharmaceuticals
• AbbVie
• Johnson & Johnson Innovative Medicine

結論與建議

Global Transthyretin Amyloidosis Treatment Market size was valued at USD 7.2 Billion in 2024 and is poised to grow from USD 8.2 Billion in 2025 to USD 23.23 Billion by 2033, growing at a CAGR of 13.9% during the forecast period (2026-2033).

The transthyretin amyloidosis treatment market is primarily driven by innovative disease-modifying therapies that shift focus from symptomatic care to altering disease progression. Current therapies emphasize methods like protein stabilization, RNA silencing, and replacement, making this market crucial as patients confront severe cardiac and neurological decline. Advances in diagnostics, including noninvasive cardiac imaging and genetic testing, enhance case identification, while approvals of therapies such as tafamidis and patisiran stimulate investment and development. The expanding diagnostic landscape fosters reliable detection and clinical benefits, encouraging adoption. Additionally, AI enhances drug discovery and patient stratification by improving target analysis and refining patient cohorts, thus reducing trial inefficiencies. These dynamics present opportunities for gene therapies and partnerships, broadening access to effective treatments in underserved regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Transthyretin Amyloidosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Transthyretin Amyloidosis Treatment Market Segments Analysis

Global transthyretin amyloidosis treatment market is segmented by drug type, disease type, application, route of administration, distribution channel, end user and region. Based on drug type, the market is segmented into Transthyretin Stabilizers, Gene Silencing Therapies, Monoclonal Antibodies, Supportive Therapies and Others. Based on disease type, the market is segmented into Hereditary ATTR Amyloidosis and Wild-Type ATTR Amyloidosis. Based on application, the market is segmented into Polyneuropathy, Cardiomyopathy and Mixed Manifestations. Based on route of administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Care Centers and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Transthyretin Amyloidosis Treatment Market

A key market driver for the global transthyretin amyloidosis (ATTR) treatment market is the increasing prevalence of the disease, which is often underdiagnosed due to its varied symptoms and complexity. Awareness and understanding of ATTR are improving among healthcare professionals and patients, resulting in more accurate diagnoses and a greater demand for effective treatments. Additionally, advancements in drug development and biotechnology have led to the introduction of novel therapies that significantly improve patient outcomes, further stimulating market growth. The rising focus on early detection and individualized treatment approaches is also propelling investment and innovation within the ATTR treatment landscape.

Restraints in the Global Transthyretin Amyloidosis Treatment Market

One of the key market restraints for the global transthyretin amyloidosis treatment market is the high cost of therapy and treatment options. These therapies, particularly innovative biologics and gene therapies, often come with significant price tags, which can limit accessibility for patients and healthcare systems, particularly in low to middle-income regions. Additionally, the complexity of diagnosing transthyretin amyloidosis can lead to delays in treatment initiation, discouraging investment from healthcare providers. This combination of high costs and diagnostic challenges might hinder market growth, as more patients struggle to obtain timely and effective treatments.

Market Trends of the Global Transthyretin Amyloidosis Treatment Market

The global market for Transthyretin Amyloidosis treatment is experiencing a notable shift driven by advances in precision diagnostics. Innovations in molecular diagnostics and biomarker profiling facilitate earlier and more accurate identification of the disease's phenotypes, which enhances the selection of tailored therapeutic approaches. This trend fosters collaboration among diagnostics companies, specialty healthcare centers, and pharmaceutical developers, resulting in improved treatment outcomes. Additionally, the integration of genetic testing into clinical pathways is reshaping patient care, making it more efficient and effective. As healthcare providers and payers increasingly adopt diagnostic-driven care models, the focus remains on optimizing outcomes while ensuring sustainable resource allocation throughout the patient journey.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Transthyretin Amyloidosis Treatment Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Transthyretin Stabilizers
• Gene Silencing Therapies
• Monoclonal Antibodies
• Supportive Therapies
• Others

Global Transthyretin Amyloidosis Treatment Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Hereditary ATTR Amyloidosis
• Wild-Type ATTR Amyloidosis

Global Transthyretin Amyloidosis Treatment Market Size by Application & CAGR (2026-2033)

• Market Overview
• Polyneuropathy
• Cardiomyopathy
• Mixed Manifestations

Global Transthyretin Amyloidosis Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Subcutaneous

Global Transthyretin Amyloidosis Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

Global Transthyretin Amyloidosis Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Care Centers
• Homecare Settings

Global Transthyretin Amyloidosis Treatment Market Size & CAGR (2026-2033)

• North America (Drug Type, Disease Type, Application, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Drug Type, Disease Type, Application, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Disease Type, Application, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Disease Type, Application, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Disease Type, Application, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Alnylam Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurimmune
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eidos Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arrowhead Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corino Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SOM Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akcea Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Innovative Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations